Based on target gene enrichment assay, the TP53 regulation was identified as one of the most commonly affected transcriptional processes after treatment of CRC with CBD (Log10(p) = −6.5) (Fig. 1d and Table 3). The gene discussed is TP53; the disease is colorectal carcinoma.